| name | Telmisartan |
| classification | Angiotensin II Receptor Blocker (ARB) |
| pharmacokinetics | | absorption | Well absorbed after oral administration, peak plasma concentrations typically reached within 1-2 hours. | | distribution | Distributed widely throughout the body, with high tissue penetration. | | metabolism | Metabolized primarily by the liver, with minimal renal elimination. | | excretion | Eliminated primarily in the urine and feces, with approximately 50% of the dose excreted as unchanged drug in the urine. |
|
| suggested dosage | | initial dosage | 40 mg once daily, titrated to 80 mg once daily as needed. | | typical maintenance dosage | 40-80 mg once daily. | | patient specific considerations | Dosage may need adjustment based on individual patient response and renal function. Consult with a physician for specific recommendations. |
|
| indications | | 1 | Hypertension | | 2 | Diabetic Nephropathy | | 3 | Chronic Kidney Disease | | 4 | Heart Failure |
|
| safety in pregnancy | | classification | Category C. | | details | Telmisartan should be used cautiously during pregnancy. Animal studies have shown adverse effects, but adequate and well-controlled studies in pregnant women are not available. The potential benefits of using the drug must be weighed against the potential risks to the fetus. |
|
| safety in breastfeeding | | classification | Not recommended. | | details | Telmisartan can be excreted in breast milk. Due to the potential for adverse effects on the infant, the drug should not be used in breastfeeding mothers or breastfeeding must be discontinued. |
|
| side effects | | 1 | Dizziness | | 2 | Headache | | 3 | Fatigue | | 4 | Lightheadedness | | 5 | Syncope | | 6 | Diarrhea | | 7 | Nausea | | 8 | Constipation | | 9 | Abdominal Pain | | 10 | Peripheral Edema | | 11 | Dry mouth | | 12 | Muscle cramps | | 13 | Cough | | 14 | Rash | | 15 | Pruritus | | 16 | Hyperkalemia (rare) |
|
| alternatives | |
| contraindications | | 1 | Hypersensitivity to telmisartan or other ARBs | | 2 | Severe hepatic impairment | | 3 | Pregnancy (Category C) |
|
| interactions | | drugs | | 1 | Lithium | | 2 | Potassium-sparing diuretics | | 3 | NSAIDs (Nonsteroidal anti-inflammatory drugs) |
| | details | Telmisartan can interact with other medications. Inform your doctor of all medications you are taking. Avoid combining telmisartan with potassium-sparing diuretics or potassium supplements, as this may lead to hyperkalemia. |
|
| warnings and precautions | | 1 | Renal impairment: Dosage adjustment may be necessary in patients with renal impairment. | | 2 | Severe hypotension: Telmisartan can cause severe hypotension, especially in patients with reduced blood volume or cardiac output. | | 3 | Elderly patients: Monitor blood pressure closely in elderly patients. | | 4 | Monitor blood potassium levels: In patients with risk of hyperkalemia (e.g. renal impairment or concurrent use of other drugs), monitor blood potassium levels closely. |
|
| additional informations | | patient age and weight consideration | For a 25-year-old male weighing 70kg, the typical dosage and considerations are outlined above. It is imperative to consult with a physician for personalized recommendations based on medical history and current health status. | | monitoring | Regular monitoring of blood pressure and kidney function is important for patients on this medication. |
|
